GlassScriptPhysician profile
Shilpa Argade
NPI 1639664592
$6,050.11
in general payments reported to CMS, 2019-2025
21 companies · $2,782 in 2025
The $2,782 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $289 · 2021: $417 · 2022: $678 · 2023: $1,145 · 2024: $452 · 2025: $2,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Travel and Lodging: $1,889 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.86 |
| Travel and Lodging | $1,888.50 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $2,167.65 | 2024-2025 | |
| Boston Scientific Corporation | $1,268.44 | 2019-2025 | General - Erectile Dysfunction, Ams 700 Cxr Rte Kit, Ams 700 |
| Baxter Healthcare | $1,047.04 | 2020-2025 | Artiss, Perclot, Floseal |
| Astellas Pharma US INC | $339.98 | 2019-2022 | |
| Endo USA, INC. | $233.10 | 2025 | Xiaflex |
| Endo Pharmaceuticals INC. | $140.41 | 2023 | Xiaflex |
| Teleflex LLC | $137.53 | 2023 | Urolift |
| Sumitomo Pharma America, INC. | $119.95 | 2025 | Gemtesa, Orgovyx |
| Neurelis, INC. | $117.93 | 2025 | Valtoco |
| Genzyme Corporation | $76.11 | 2025 | |
| Janssen Biotech, INC. | $65.00 | 2023 | Erleada |
| Verity Pharmaceuticals INC. | $59.02 | 2025 | Trelstar, Tlando |
| Antares Pharma, INC. | $50.00 | 2023 | Tlando, Xyosted |
| Photocure INC | $44.39 | 2021 | |
| Medtronic, INC. | $41.24 | 2025 | Interstim |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $28.23 | 2025 | |
| Abbvie INC. | $27.26 | 2025 | |
| Pfizer INC. | $24.71 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $24.06 | 2025 | Bard Urinary Drainage Bag |
| Biotissue Holdings INC. | $20.55 | 2025 | |
| Ferring Pharmaceuticals INC. | $17.51 | 2025 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Argade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.